Anika Therapeutics, Inc. (ANIK)
- Previous Close
25.79 - Open
25.78 - Bid 25.80 x 100
- Ask 26.07 x 100
- Day's Range
25.78 - 26.14 - 52 Week Range
16.54 - 28.13 - Volume
30,594 - Avg. Volume
82,640 - Market Cap (intraday)
384.612M - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-5.64 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.33
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
www.anika.comRecent News: ANIK
Performance Overview: ANIK
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANIK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANIK
Valuation Measures
Market Cap
384.61M
Enterprise Value
340.78M
Trailing P/E
--
Forward P/E
23.15
PEG Ratio (5yr expected)
2.31
Price/Sales (ttm)
2.28
Price/Book (mrq)
1.81
Enterprise Value/Revenue
2.04
Enterprise Value/EBITDA
-30.34
Financial Highlights
Profitability and Income Statement
Profit Margin
-49.60%
Return on Assets (ttm)
-2.36%
Return on Equity (ttm)
-33.21%
Revenue (ttm)
166.66M
Net Income Avi to Common (ttm)
-82.67M
Diluted EPS (ttm)
-5.64
Balance Sheet and Cash Flow
Total Cash (mrq)
72.87M
Total Debt/Equity (mrq)
13.68%
Levered Free Cash Flow (ttm)
12.58M
Research Analysis: ANIK
Company Insights: ANIK
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ANIK
ANIK: Lowering target price to $18.00
ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $18.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetANIK: Lowering target price to $19.00
ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetANIK: What does Argus have to say about ANIK?
ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetANIK: Lowering target price to $20.00
ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target